Bumetanide (Bumex)
Potent loop diuretic structurally different from furosemide; high lipid solubility allows passive diffusion to tubular site of action (vs active secretion for furosemide). Peak plasma levels ~30 min after oral dose; short half-life balanced by potency. ~95% plasma protein bound; metabolized via butyl side-chain degradation and partial renal excretion. Used for edema, heart failure. Approximately 40x more potent than furosemide by weight.
Projected serum levels — 1 mg, once daily
Maintenance schedule: 1 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 0.47 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Diuretic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 1.2 h
- Common dose
- 1 mg
- Suggested maximum
- 10 mg/day
- Reference dose range
- 0.50–10 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 1 mg oral — Cmax 0.055 mg/L at 1 h
Documented interactions
-
warning
Aspirin (Acetylsalicylic Acid) + Bumetanide (Bumex)
NSAID reduces diuretic effect.
-
warning
Ibuprofen (Advil / Motrin) + Bumetanide (Bumex)
NSAID impairs loop diuretic efficacy.
-
warning
Lithium Orotate (Microdose) + Bumetanide (Bumex)
Loop diuretic reduces lithium clearance, increasing toxicity risk.
Serum checks 3 modeled interaction pairings for bumetanide (bumex) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new 'loop' diuretic
Comprehensive review of bumetanide pharmacology, showing potency ~40-fold greater than furosemide, rapid absorption with peak plasma levels at 30 min, and metabolism via side-chain cleavage.
-
Pharmacokinetics of intravenously administered bumetanide in man
PK study demonstrating apparent half-life 1.0-1.5 hours, volume of distribution ~25 liters, total plasma clearance ~228 ml/min, renal clearance ~half of total clearance.
-
Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use
Systematic review establishing bumetanide as potent loop diuretic with rapid absorption, short half-life, high protein binding, and favorable use in edema and CHF compared to furosemide.
3 published studies referenced in the app, each with a plain-language summary.